Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog – Page 3

Get the latest international news and world events from around the world.

Log in for authorized contributors

SpaceX Wants Its Own Gas Pipeline to Feed All the Starships

Elon Musk’s rocket company is taking one step further in controlling nearly every stage of its supply chain, building its own natural gas infrastructure to fuel upcoming Starship launches.

SpaceX plans on building a natural gas pipeline stretching across 8 miles (14 kilometers) to its Starbase facility in Texas, Reuters reported based on county filings. The pipeline, called Starpipe, is expected to provide enough propellant for SpaceX’s Starship rocket to fly dozens of times a year.

The move highlights SpaceX’s vision to maintain end-to-end control of its supply chain, minimizing the company’s dependence on outside providers for much-needed resources.

Scientists found an 8-year-old Neanderthal child in a Belgian cave, and the molar DNA found is said to be the oldest human genetic code ever sequenced, turning one hillside into a rare window on our deep past

Scientists have uncovered the oldest human genetic code from an 8-year-old Neanderthal child in Belgium, offering profound insights into our evolutionary past and Neanderthal development.

How GE Vernova builds the massive gas turbines powering the AI data center boom

“When we think of what the world needs for electrification and what we need to power this AI surge that we’re living, a lot of that stuff comes right out of this factory,” said Koziner.

Microsoft just bought seven of them to power its data center in Texas. At 2.7 gigawatts, it’s enough electricity to power about 3 million homes.

GE Vernova turbines are already online at Elon Musk’s xAI Colossus 1 campus in Tennessee, and nearly a gigawatt more are being deployed at OpenAI’s Stargate project in Texas, according to Cleanview, an organization that tracks data center development.

A selective, brain-penetrant GalR1 antagonist restores cholinergic signaling in vitro and rescues cholinergic cognitive deficits in mice

In this study, we characterized PAC-832, a small-molecule GalR1 antagonist with sub-micromolar potency (IC50 = 0.28 μM), 30-fold selectivity over GalR2 and GalR3, and excellent brain penetration and drug-like properties. In functional cell-based assays, PAC-832 reversed galanin-mediated suppression of acetylcholine release. In a scopolamine challenge model, PAC-832 attenuated cognitive deficits in the Y-maze and NOR tasks, with effect sizes comparable to donepezil.

The scopolamine model is widely used in behavioral mouse research to evaluate compounds for procognitive activity. However, because scopolamine impairs cognition by blocking muscarinic receptors rather than by reducing acetylcholine release, our behavioral results do not directly assess whether PAC-832 acts by restoring cholinergic signaling in vivo, or whether it acts through an alternative downstream mechanism. Establishing the former will require direct measurement of acetylcholine release in the CNS (e.g. using microdialysis or biosensor-based approaches) and/or GalR1-dependent in vivo validation (e.g. using transgenic GalR1-knockout mice).

Nonetheless, our work addresses a longstanding pharmacological gap in the galanin field. Despite decades of work implicating galanin signaling in CNS function and disease, translational progress has been limited by a lack of subtype-selective, brain-penetrant small molecule galanin modulators. Recent therapeutic development within the galanin field has largely focused on GalR2 agonism, while GalR1-targeting approaches have remained dependent on peptide tools unable to pass the blood-brain barrier. PAC-832 is, to our knowledge, the first GalR1-selective small molecule antagonist with sufficient brain exposure to test the effects of GalR1 antagonism following peripheral administration.

Chemical impurities make carbon surfaces superslippery, researchers find

Engineers often treat impurities as a problem to eliminate to improve material performance. But new research from Osaka Metropolitan University and Fraunhofer Institute for Mechanics of Materials IWM suggests that in some cases, a little chemical messiness is exactly what helps materials slide more smoothly. The findings were published in Advanced Science.

When two surfaces slide or rub against each other, friction occurs. While friction is essential for many everyday applications, it also wears down machines, wastes energy and limits the lifespan of moving parts. Therefore, research has focused on achieving superlow friction, or superlubricity, in which surfaces can slide past one another with exceptionally low resistance.

“While graphene-or graphite-like structures are known to enable nearly frictionless sliding, creating and maintaining such structures in practical systems remains challenging,” said Takuya Kuwahara, lecturer at Osaka Metropolitan University’s Graduate School of Engineering and lead author of the study.

A species of gut bacteria could ease anxiety and diarrhea-predominant IBS

Irritable bowel syndrome (IBS) is a condition characterized by abdominal pain, bloating and changes in bowel movements, estimated to affect between 10% and 15% of people worldwide. Past studies suggest that in many cases this condition is accompanied by anxiety, an emotional state marked by worry, fear and/or overthinking about specific life events.

While IBS and anxiety are known to often occur together, the biological processes linking the two have not yet been fully elucidated. One possibility is that bacteria and other microorganisms living in the digestive tract, broadly referred to as gut microbiota, contribute to these biological processes.

Researchers at Wuhan University of Science and Technology and Huazhong University of Science and Technology carried out a study aimed at shedding more light on the biological mechanisms linking a type of IBS called diarrhea-predominant IBS (IBS-D), which is associated with frequent loose stools, with anxiety.

Single-cell dissection of plasma cell clonal evolution to smoldering multiple myeloma after CD19 CAR-T cell therapy in B-cell acute lymphoblastic leukemia

Chimeric antigen receptor T (CAR-T) cell therapy has revolutionized the treatment of B-cell malignancies, achieving deep and durable remissions in patients with B-cell acute lymphoblastic leukemia (B-ALL).1 Despite remarkable therapeutic successes, rare but clinically significant secondary hematologic malignancies have been reported during CAR-T cell therapy, often driven by lineage switching or clonal selection.2 Moreover, CAR-T cell therapy drives profound remodeling of the immune microenvironment, and the sustained inflammatory signaling may promote clonal evolution and influence disease progression.3 High-resolution approaches, such as single-cell RNA sequencing (scRNA-seq) and single-cell B-cell receptor sequencing (scBCR-seq), enable characterization of transcriptional programs, clonal identity, and temporal dynamics to dissect CAR-T cell therapy-induced clonal evolution and immune remodeling.4

Here, we report a case of B-ALL with B-cell receptor (BCR) heterogeneity at diagnosis that evolved into smoldering multiple myeloma (SMM) following CD19-targeted CAR-T therapy. The co-occurrence of B-ALL and SMM is exceptionally rare, as it requires malignant clones at distinct stages of B-cell development. This case provides a unique opportunity to dissect how CAR-T cell therapy drives B-lineage clonal evolution and reshapes the immune microenvironment. To this end, bone marrow mononuclear cells (BMMNC) were collected at multiple time points and subjected to longitudinal scRNA-seq and scBCR-seq to track dynamic changes in malignant and immune cell populations, thereby elucidating the mechanisms of clonal evolution and immune remodeling following CAR-T cell therapy. The patient gave informed consent and was enrolled in a clinical trial registered at clinicaltrials.gov (Identifier: NCT00123456).

A 13-second eye test may help predict recovery of consciousness after severe brain injury

A simple bedside eye test may help predict recovery of consciousness in patients with severe brain injuries, according to new research presented at the European Academy of Neurology (EAN) Congress 2026.

The study found that a previously overlooked phase of the pupil response to light, known as the late light-off response (LOR), predicted improvements in consciousness seven days later in patients with acute brain injury. In contrast, standard pupil measurements already widely used in intensive care units (ICUs), including the Neurological Pupil Index (NPi) and pupillary light reflex (PLR) latency, did not predict later gains in consciousness.

Newly identified fossil sheds light on evolutionary history of saber-toothed cats

Fossils tucked away in a museum drawer and identified merely as “feline” are actually from a very ancient and enigmatic saber-toothed cat that inhabited North America more than 5 million years ago. Newly identified by a UC Berkeley paleontologist, the nearly complete skull helps clarify how these large-fanged felines evolved over millennia before going extinct about 10,000 years ago.

One clear takeaway is that these cats started out with smaller fangs—the upper canines—but evolved increasingly longer ones that may have led to their ultimate demise. California’s state fossil, Smilodon fatalis (originally called S. californicus), was the culmination of that trend. It had some of the largest upper canines of any saber-toothed animal—up to 7 inches (18 centimeters) long—but was the last saber-toothed animal to survive.

According to Berkeley postdoctoral fellow Narimane Chatar, the cranium, teeth and lower jaw (or mandible) she stumbled upon in the American Museum of Natural History in New York are from the species Adelphailurus kansensis, originally discovered in Kansas and known only from jaw fragments and teeth. Now, with the first complete skull of the cat, she has been able to tentatively place the animal within the family tree of saber-toothed carnivores and contrast it with the most recognizable saber-toothed cat, Smilodon, which ranged throughout the Americas.

/* */